Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

ARNA 4.37 -0.11 (-2.46%)
price chart
A Realistic View Of Belviq In The Short Term
Over my 10-year career trading biotechs, I have found that retail investors are all too often unrealistic about new therapies and the subsequent appreciation of a company's common stock. The retail crowd surrounding ARNA appears to be repeating this ...
Related articles »  
South Korea's Ildong Pharma To License Arena Pharma Drug
29, 2012) - U.S.-based Arena Pharmaceuticals, Inc. has licensed its internally discovered thrombosis drug, temanogrel, to Seoul, Korea-based Ildong Pharmaceutical Co.
Related articles »  
Vivus Or Arena: Who Has The Edge?
Two of the three major players in the treatment of obesity, VIVUS Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals Inc. (NASDAQ:ARNA) released their financial results and provided an update on recent developments.
Related articles »  
CEO of the Year, Final Round: Arena Pharmaceuticals vs. Lumber Liquidators
On one hand we have Jack Lief of Arena Pharmaceuticals, who led his company to develop Belviq, the anti-obesity drug recently approved by the FDA that's currently in the driver's seat to be the first fat-busting drug approved internationally (all ...
Arena Pharma Is Still A Good Short
My advice to lorcaserin bulls would be to cherish the moment but sell the stock...This is as good as it gets. If you're one of the lucky few that can find shares to borrow, congrats -- you've got a good short.
Related articles »  
Vivus, Arena shares jump on insurance coverage for diet pills
O) and Arena Pharmaceuticals Inc (ARNA.O), sending the obesity drugmakers' shares up. The decision by the third-largest health insurer to provide coverage for Vivus' Qsymia and Arena's Belviq may boost adoption of the diet pills.
Vivus Jumps on Aetna Qsymia Ruling: San Francisco Mover  Bloomberg
Vivus, Arena, Orexigen Get a Bounce After Aetna Says It Will Cover Diet Pills
Related articles »  
Arena Pharma Sinks Under Weight Of Vivus' Troubles
Despite having split economics on Belviq, ARNA now trades at a substantial premium to VVUS. The most worrisome disclosure by Vivus Tuesday was the fact that 30% of patients willing to try Qsymia and who get actually get a prescription from their doctor ...
Related articles »  
Indian board rejects AstraZeneca's patent plea on cancer drug
Natco and another domestic drugmaker, G. M. Pharma, had opposed the initial patent application for AstraZeneca quinazoline derivative.
Related articles »  
Amgen Therapy Slims Monkeys as Study Seeks Obesity Drug
Nov. 28 (Bloomberg) -- An antibody discovered by Amgen Inc. researchers reduces weight and increases glucose tolerance in monkeys, according to a study, potentially opening up a new approach for treating obesity and diabetes in humans.
Related articles »  
Vivus Inc: This Hedge Fund Just Went Activist
And then there's Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and a few other competitors. Belviq is the major competition to Qsymia, and with far fewer contraindications, Belviq is more likely to be the first-prescribed drug between Qsymia and Bevliq ...
Related articles »